# Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer

> **NCT01004380** · PHASE1 · COMPLETED · sponsor: **Morphotek** · enrollment: 15 (actual)

## Conditions studied

- Epithelial Ovarian Cancer

## Interventions

- **DRUG:** Farletuzumab, Carboplatin, and PLD

## Key facts

- **NCT ID:** NCT01004380
- **Lead sponsor:** Morphotek
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2012-08
- **Final completion:** 2012-10
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2014-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01004380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01004380, "Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01004380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*